<DOC>
	<DOCNO>NCT02562573</DOCNO>
	<brief_summary>This Phase 2 , open-label , single-arm study safety tolerability PBI-4050 800 mg daily oral administration type 2 diabetes patient metabolic syndrome . A total 12 patient initially enrol study participation . A Data Safety Monitoring Board ( DSMB ) continuously review data obtain 12 patient . When 12 patient complete least one month study treatment , DSMB meet determine whether additional patient may enrol study stop . If safety deem acceptable continue study , study enroll maximum 36 patient .</brief_summary>
	<brief_title>Study Evaluate Safety Tolerability PBI-4050 Type 2 Diabetes Patients With Metabolic Syndrome</brief_title>
	<detailed_description>This Phase 2 study perform 1 site Canada . The total duration study participation patient least 18 week comprise 6 study visit . Patients choose participate extension study study total 32 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>1 . Patient 18 year age old . 2 . Patient sign write informed consent . 3 . Patient clinical diagnosis type 2 diabetes mellitus hemoglobin A1c ( HbA1c ) level 7 % 10 % . 4 . Patient receive stable antidiabetic therapy ( oral agent without basal insulin give daily even ) minimum 3 month screen visit . 5 . Patient able willing selfmonitor blood glucose level home . 6 . Patient body mass index ( BMI ) least 27 kg/m2 . 7 . Patient metabolic syndrome , least 3 5 metabolic syndrome risk factor . 1 . Patient require intensive insulin therapy ( define basal insulin give daily even ) addition oral hypoglycemic agent blood glucose control . 2 . Patient recent ongoing infection require systemic treatment antiinfective agent within 30 day screen . 3 . Patient least one episode severe hypoglycemia past 12 month , define blood glucose level &lt; 3.0 mmol/L and/or require third party assistance treat hypoglycemic episode . 4 . Patient evidence significant cardiovascular disease , include myocardial infarction , unstable angina , coronary bypass surgery , percutaneous transluminal coronary angioplasty ( PTCA ) , congestive heart failure ( New York Heart Association Class IIIIV ) , stroke , severe ischemic disease within 3 month screen . 5 . Patient uncontrolled hypertension BP &gt; 150/95 mm Hg . 6 . Patient diagnosis rheumatic inflammatory disease , rheumatoid arthritis ( RA ) , polymyalgia rheumatic ( PMR ) , inflammatory bowel disease ( IBD ) ; autoimmune inflammatory disease systemic lupus erythematosus ( SLE ) psoriasis . 7 . Patient concurrently take plan routinely continue take antiinflammatory medication , nonsteroidal antiinflammatory drug ( NSAIDs ) corticosteroid , study . 8 . Patient currently use weight loss medication . 9 . Patient significantly elevate liver enzyme level , define alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥ 2.5 × upper limit normal ( ULN ) total bilirubin ULN . 10 . Patient history chronic alcohol substance abuse . 11 . Woman pregnant , breastfeeding , plan pregnancy course study . 12 . Woman childbearing potential unwilling use adequate birth control throughout duration study . 13 . Patient condition , investigator 's opinion , likely interfere study conduct compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>